Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		It was not used in this study.

Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		It was not used in this study.
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		It was not used in this study.

Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		It was not used in this study.
Animal observed in or captured from the field: Provide species, sex and age where possible		It was not used in this study.
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		It was not used in this study.

Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		It was not used in this study.
Microbes: provide species and strain, unique accession number if available, and source		It was not used in this study.

Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page3 /line 25-26 Patients and methods/Para1	
Provide statement confirming informed consent obtained from study participants.	Page3 /line 26-27 Patients and methods/Para1	
Report on age and sex for all study participants.	Table 1	

Design

Study protocol	Yes (indicate where	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		This study is a retrospective study, and the registration number cannot be provided at present.

Laboratory protocol	Yes (indicate where	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		This study does not involve laboratory protocol.

Experimental study design (statistics details)	Yes (indicate where	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination		This is a preliminary exploratory study and the sample size was not calculated.
Randomisation		This is an exploratory study and does not involve randomization.
Blinding		No blinding method is involved in this study.
Inclusion/exclusion criteria	Inclusion criteria: Page2/Line10-12 Abstract/Para 2; Page3/Line 19-21 Patients and methods/Para1 Exclusion criteria: Page3/Line 21-23 Patients and methods/Para1	

Sample definition and in-laboratory replication	Yes (indicate where	n/a
State number of times the experiment was replicated in laboratory		This is a retrospective clinical study and does not involve replication.
Define whether data describe technical or biological replicates		This is a retrospective clinical study and does not involve replication.

Ethics	Yes (indicate where	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page3 /line 25-26 Patients and methods/Para1	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		Experimental animals were not included in this study.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		This study does not involve specimen or field samples.

Dual Use Research of Concern (DURC)	Yes (indicate where	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		This study does not involve dual use research of concern.

Analysis

Attrition	Yes (indicate where	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Page3/line21-23 Patients and methods/Para1	

Statistics	Yes (indicate where	n/a
Describe statistical tests used and justify choice of tests.		This is an exploratory study, which is mainly descriptive and does not involve data statistics.

Data Availability	Yes (indicate where	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		This is an exploratory study. The datasets are still being supplemented and are not available at this time.
If data are publicly available, provide accession number in repository or DOI or URL.		The data are not publicly available.
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		The data are not publicly available.

Code Availability	Yes (indicate where	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		There is no newly generated code or software.
If code is publicly available, provide accession number in repository, or DOI or URL.		There is no newly generated code or software.

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	Section Acknowledgement.	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/tau-20-1055.